ライフサイエンスコーパス: lipoatrophy

1 cyte marker gene expression and subcutaneous lipoatrophy.

2 ients but can worsen glucose homeostasis and lipoatrophy.

3 exercise-induced hypothalamic amenorrhea and lipoatrophy.

4 ssue basis of the increased REE shown in HIV lipoatrophy.

5 uscle is hypermetabolic in patients with HIV lipoatrophy.

6 resting hypermetabolism of patients with HIV lipoatrophy.

7 sed relationships between these variants and lipoatrophy.

8 ve been implicated in the development of HIV lipoatrophy.

9 ohypertrophy, and fat wasting, also known as lipoatrophy.

10 ients with relative leptin deficiency due to lipoatrophy.

11 low levels of adiponectin and leptin due to lipoatrophy.

12 ood model for humans with severe generalized lipoatrophy.

13 le in causing the metabolic complications of lipoatrophy.

14 lving extremities, occasionally resulting in lipoatrophy.

15 5%; P = .02) and were less likely to develop lipoatrophy after adjustment for age, sex, race, and ART

16 rt stature, intrauterine growth restriction, lipoatrophy and a facial gestalt involving a triangular

17 ockout mice exhibit a prominent phenotype of lipoatrophy and are resistant to high-fat diet-induced o

18 Pparg(Delta/Delta) mice exhibited total lipoatrophy and complete absence of sebaceous glands.

19 and dermal fibrosis as well as subcutaneous lipoatrophy and counteracted the up-regulation of collag

20 Variable lipoatrophy and cutis laxa are the basis for a progeroid

21 ence of both insulin and adiponectin, severe lipoatrophy and hyperlipidemia lead to lethality.

22 Ncb5or deficiency also results in lipoatrophy and increased hepatocyte sensitivity to cyto

23 nectin levels, in HIV-infected patients with lipoatrophy and insulin resistance.

24 maraviroc counterregulated ritonavir-induced lipoatrophy and interlelukin-6 gene expression in epidid

25 in children with atrophic disorders such as lipoatrophy and morphea.

26 of cells caused extreme growth retardation, lipoatrophy, and hypoglycemia, a clinical constellation

27 cells and the observable levels of fibrosis, lipoatrophy, and lymphocytic infiltration were reduced i

28 atitis, peripheral neuropathy, lipodystrophy/lipoatrophy, and pancreatitis, whereas the most common l

29 tion in patients with lipoatrophy, including lipoatrophy associated with HIV or highly active antiret

30 s poly-L-lactic acid were first approved for lipoatrophy associated with human immunodeficiency virus

31 IRS-1 and IRS-3 developed early-onset severe lipoatrophy associated with marked hyperglycemia, hyperi

32 Increased REE in subjects with HIV lipoatrophy cannot be explained by differences in organ-

33 resulting in similar growth retardation and lipoatrophy, caused diabetes without beta-cell hyperplas

34 Severe adipose tissue deficiency (lipoatrophy) causes insulin-resistant diabetes, elevated

35 Subcutaneous lipoatrophy characteristically accompanies dermal fibros

36 aplogroup J gave relative protection against lipoatrophy during ART in A5005s.

37 erized by a prematurely aged appearance with lipoatrophy, epidermal and dermal atrophy along with hyp

38 Facial lipoatrophy (FLA) is associated with human immunodeficie

39 l filler in patients with HIV-related facial lipoatrophy (FLA).

40 Here we have identified evidence of partial lipoatrophy in Reep1 null mice in addition to prominent

41 ant role in the pathogenesis of fibrosis and lipoatrophy in SSc.

42 roves metabolic dysfunction in patients with lipoatrophy, including lipoatrophy associated with HIV o

43 strated positive effects of rosiglitazone on lipoatrophy; insulin sensitivity; and metabolic indices,

44 Antiretroviral therapy (ART)-associated lipoatrophy involves mitochondrial dysfunction.

45 immunodeficiency virus (HIV)-related facial lipoatrophy is a devastating adverse effect of antiretro

46 rse transcriptase inhibitors as the cause of lipoatrophy led to the development of newer antiretrovir

47 Focal adipose deficiency, such as lipoatrophy, lumpectomy or facial trauma, is a formidabl

48 kin histology revealed that inflammation and lipoatrophy may be chief disease mediators in patients.

49 nal obesity and stavudine-induced peripheral lipoatrophy, might contribute to the higher prevalence o

50 ed by a progressive cellular and peristromal lipoatrophy of epithelial cell cytology and metabolic pa

51 We find that Lpin1 null mutations lead to lipoatrophy of the epineurium, and to the dysregulation

52 DIDO mutation caused hypothermia due to lipoatrophy of white adipose tissue (WAT) and dermal fat

53 Lipoatrophy persisted in KO animals in which the confoun

54 although less severe, is reminiscent of the lipoatrophy phenotype observed in the most common form o

55 t function, as suggested by the diabetes and lipoatrophy phenotypes in Ncb5or null mice.

56 on of Pla2g7 in mice showed decreased thymic lipoatrophy, protection against age-related inflammation

57 tients with HIV-associated FLA, a Carruthers Lipoatrophy Severity Scale (CLSS) grade of 2 or greater

58 asured REE remained significantly greater in lipoatrophy subjects after routine adjustment for lean b

59 individuals with hypoleptinemia secondary to lipoatrophy such as in individuals with generalized lipo

60 The HIV lipoatrophy syndrome is characterized by loss of subcuta

61 y estimate a higher prevalence of peripheral lipoatrophy than does MRI in HIV+ subjects.

62 E was significantly greater in subjects with lipoatrophy than in control subjects.

63 lammation, dermal fibrosis, and subcutaneous lipoatrophy via PPAR-gamma in a mouse model of scleroder

64 need to be different in those patients with lipoatrophy when compared with patients with central fat

65 aP2-cre-mediated GRP78 deletion leads to lipoatrophy with approximately 90% reduction in gonadal

66 phy, characterized by subcutaneous fat loss (lipoatrophy), with or without central fat accumulation (

67 d an age-dependent loss of adipose tissue or lipoatrophy, with all observed adipose depots dramatical